Company Filing History:
Years Active: 2020-2021
Title: John Randall Slemmon: Innovator in Neurodegeneration Detection
Introduction
John Randall Slemmon is a notable inventor based in West Windsor, NJ (US). He has made significant contributions to the field of neurodegeneration detection, holding a total of 2 patents. His work focuses on innovative methods for diagnosing and treating tauopathies, which are critical for advancing medical science.
Latest Patents
Slemmon's latest patents include groundbreaking methods for measuring the amount of singly- or multiply-phosphorylated p217+ tau protein in a sample. These methods are essential for detecting or diagnosing tauopathies. Additionally, they provide techniques for determining the effectiveness of treatments for tauopathies and assessing whether a subject is suitable for anti-p217+ tau antibody therapy. His patents also describe antibodies for use in these methods and kits that comprise these antibodies.
Career Highlights
John Randall Slemmon is currently associated with Janssen Pharmaceutica NV, where he continues to innovate in the field of neurodegeneration. His work has the potential to significantly impact the diagnosis and treatment of neurodegenerative diseases.
Collaborations
Some of his notable coworkers include Hartmuth C Kolb and Gallen Triana-Baltzer, who contribute to the collaborative efforts in research and development within the company.
Conclusion
John Randall Slemmon's contributions to neurodegeneration detection through his patents and work at Janssen Pharmaceutica NV highlight his importance in the field. His innovative methods are paving the way for advancements in the diagnosis and treatment of tauopathies.